Progressing stroke is associated poor functional outcome and neurological deficit. Currently, no treatment for progressing stroke is recommended on the guideline. Carbogen is a mixture of 5% CO2 with 95% O2. Carbogen is safe and it is used for the treatment of sudden sensory neural hearing loss or ocular ischemia. CO2 dilate cerebral arteriole and concentration of CO2 is correlated with cerebral blood flow. Increased cerebral blood flow following dilation of cerebral arteriole by CO2 might halt and revert progressing stroke. Induced hypertension is alternative treatment of progressing stroke. Increasing blood pressure also induce cerebral blood flow. Phenylephrine is an α1 agonist, phenylephrine act on peripheral artery and little effect on cerebral artery or heart. Several studies reported that the effectiveness of phenylephrine on progressing stroke. Therefore, this study will compare the effectiveness of carbogen + phenyleprhine versus phenlyephrine in progressing stroke patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
percent improvement of NIHSS score in each group
Timeframe: 24 hours
difference of NIHSS score in each group
Timeframe: 24 hours
percent improvement of MRC score in each group
Timeframe: within 24 hours
difference of MRC score in each group
Timeframe: difference of MRC score in each group
Saftety outcome: Side effect
Timeframe: within 7 days
Saftety outcome: discontinuing patients
Timeframe: within 7 days